Craig Berger, MD
Ophthalmology · Tampa, FLNPI 1023031788
Payments from drug & device makers
Across 313 payments — averaging $54.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$7K
- Avedro Inc.$2K
- Alcon$1K
- Bausch & Lomb Americas Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$690
- AbbVie$661
- plus $4K from 26 others
What the payments were for
- Consulting fees$3,28519%
- Speaking & faculty fees$3,03918%
- Travel & lodging$3592%
- Food & beverage$10,35561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 56 | $6,548 |
| Avedro Inc. | 1 | $2,450 |
| Alcon | 24 | $1,299 |
| Bausch & Lomb Americas Inc. | 32 | $1,045 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $690 |
| AbbVie(2 entities) | 26 | $661 |
| Mallinckrodt Hospital Products Inc. | 18 | $585 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $492 |
| Sun Pharmaceutical Industries Inc. | 22 | $455 |
| Oyster Point Pharma, Inc. | 17 | $429 |
| Novartis | 17 | $366 |
| Dompe US, Inc. | 10 | $298 |
| Rxsight Inc | 6 | $261 |
| Kala Pharmaceuticals, Inc. | 12 | $233 |
| Tarsus Pharmaceuticals, Inc. | 4 | $216 |
| Aerie Pharmaceuticals, Inc. | 6 | $198 |
| ANI Pharmaceuticals, Inc. | 5 | $146 |
| Shire North American Group Inc | 5 | $103 |
| Harrow Eye, LLC | 3 | $74 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Amgen | 3 | $63 |
| Sight Sciences, Inc. | 3 | $50 |
| Biotissue Holdings Inc. | 2 | $48 |
| Ziemer USA | 2 | $46 |
| NEW World Medical,inc. | 2 | $41 |
| Lombart Brothers, Inc. | 1 | $41 |
| ABB Con-cise Optical Group LLC | 4 | $36 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Akorn Operating Company LLC | 1 | $17 |
| Alcon Research LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$3,800
- Tecnis 1-piece IOL$359
- Tecnis Multifocal Family of 1-piece IOLS$359
- Tecnis Symfony IOL$359
- MIEBO$351
- Clareon$267
- Photrexa Viscous and Photrexa$263
- DURYSTA$240
- RXSIGHT INJECTOR HANDPIECE$149
- RXSIGHT CONTACT LENS$149
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$149
- RXSIGHT INJECTOR CARTRIDGE$149
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$149
- XDEMVY$137
- TRYPTYR$136
- Clareon PanOptix Pro$134
- AcrySof IQ VIVITY$127
- XIIDRA$125
- ACTHAR$125
- VUITY$123
How this compares
$17,038 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 163 | $178,933 |
| MieboPerfluorohexyloctane/Pf | 81 | $64,337 |
| XiidraLifitegrast | 54 | $54,168 |
| Lotemax SmLoteprednol Etabonate | 103 | $35,022 |
| Cyclosporine | 39 | $30,485 |
| XdemvyLotilaner | 16 | $29,161 |
| CequaCyclosporine | 23 | $20,147 |
| TyrvayaVarenicline Tartrate | 24 | $18,251 |
| LotemaxLoteprednol Etabonate | 48 | $17,952 |
| Loteprednol Etabonate | 57 | $13,293 |
| Prednisolone Acetate | 209 | $9,073 |
| LumiganBimatoprost | 16 | $8,708 |
| Brimonidine Tartrate | 74 | $7,934 |
| Alphagan PBrimonidine Tartrate | 17 | $6,810 |
| BesivanceBesifloxacin Hcl | 24 | $5,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $661 | $199,255214 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $1,045 | $118,505135 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Lotemax, Loteprednol Etabonate, Besivance | $690 | $71,716232 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $216 | $29,16116 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $455 | $20,14723 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $429 | $18,25124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Tampa
- Ivan SunerTampa$3.7M
- Pedram HamrahTampa$2.2M
- Thomas NewsomTampa$1.5M
- Courtney BoveeTampa$884K
- Ashley CraneTampa$491K
- Don PerezTampa$367K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.